A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients
Citation Information :
Shetty A, Chandrakant NS, Darnule RA, Manjunath B, Sathe P. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients. Indian J Crit Care Med 2022; 26 (8):913-919.
Background: From an epidemic outbreak, coronavirus disease-2019 (COVID-19) has quickly developed. Thymosin α1 (Tα1) has the ability to boost the T-cell numbers, support T-cell differentiation, maturation, and reduce cell apoptosis. In this study, we have investigated the efficacy and safety of Tα1 in moderate-to-severe COVID-19 patients.
Patients and methods: In this double-blind, multicenter, two-arm, randomized, placebo-controlled, phase III clinical study, patients were randomized to receive either Tα1 or placebo in combination with standard of care (SOC). The data on all-cause mortality, clinical progression/deterioration, duration of hospital/intensive care unit (ICU) stay, and safety data were collected. The patients were telephonically followed up on Day 28.
Results: A total of (n = 105) COVID-19 patients were included in the study, of which 40 and 65 were severe and moderate, respectively. Thymosin arm (11.1%) had a statistically lower death rate in comparison to the placebo arm (38.5%). A total of 67 adverse events were reported in 42 patients among 105 dosed patients during the study. Among them, 43 adverse events were of mild in nature, 16 adverse events were of moderate in nature, and 8 serious adverse events (death) occurred during the study.
Conclusion: This study provides evidence that Tα1 can lower death rate in severe COVID-19 patients, reduce the load on hospitals by shortening the required number of days of hospitalization and help in abbreviating the requirement of oxygen support by positively impacting the recovery rate and time taken for recovery.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727–733. DOI: 10.1056/NEJMoa2001017.
Yi Y, Lagniton PNP, Ye S, Li E, Xu R-H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020;16(10):1753–1766. DOI: 10.7150/ijbs.45134.
Yang P, Wang X. COVID-19: A new challenge for human beings. Cell Mol Immunol 2020;17(5):555–557. DOI: 10.1038/s41423-020-0407-x.
Garaci E. From thymus to cystic fibrosis: The amazing life of thymosin alpha 1. Expert Opin Biol Ther 2018;18(Suppl. 1):9–11. DOI: 10.1080/14712598.2018.1484447.
Zatz MM, Oliver J, Samuels C, Skotnicki AB, Sztein MB, Goldstein AL. Thymosin increases production of T-cell growth factor by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1984;81(9):2882–2885. DOI: 10.1073/pnas.81.9.2882.
Naylor PH, Mutchnick MG. Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. J Viral Hepat 2018;25(1):4–9. DOI: 10.1111/jvh.12807.
Sherman KE. Thymosin alpha 1 for treatment of hepatitis C virus: Promise and proof. Ann N Y Acad Sci 2010;1194:136–140. DOI: 10.1111/j.1749-6632.2010.05460.x.
Matteucci C, Grelli S, Balestrieri E, Minutolo A, Argaw–Denboba A, Macchi B, et al. Thymosin alpha 1 and HIV-1: Recent advances and future perspectives. Future Microbiol 2017;12:141–155. DOI: 10.2217/fmb-2016-0125.
Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, et al. Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis Off Publ Infect Dis Soc Am 2020;71(16):2150–2157. DOI: 10.1093/cid/ciaa630.
Sun Q, Xie J, Zheng R, Li X, Chen H, Tong Z, et al. The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study. Int Immunopharmacol 2021;90:107143. DOI: 10.1016/j.intimp.2020.107143.
Wu M, Ji JJ, Zhong L, Shao ZY, Xie QF, Liu ZY, et al. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Int Immunopharmacol 2020;88:106873. DOI: 10.1016/j.intimp.2020.106873.
Bersanelli M, Giannarelli D, Leonetti A, Buti S, Tiseo M, Nouvenne A, et al. The right immune-modulation at the right time: Thymosin α1 for prevention of severe COVID-19 in cancer patients. Future Oncol Lond Engl 2021;17(9):1097–1104. DOI: 10.2217/fon-2020-0754.
Romani L, Tomino C, Puccetti P, Garaci E. Off-label therapy targeting pathogenic inflammation in COVID-19. Cell Death Discov 2020;6:49. DOI: 10.1038/s41420-020-0283-2.
Matteucci C, Minutolo A, Balestrieri E, Petrone V, Fanelli M, Malagnino V, et al. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients. Open Forum Infect Dis 2021;8(1):ofaa588.
Rangappa P. Cytokine Storm and Immunomodulation in COVID-19. Indian J Crit Care Med 2021;25(11):1288–1291. DOI: 10.5005/jp- journals-10071-24029.
Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S, Hulkoti V, et al. Interleukin 6 and tts correlation with COVID-19 in terms of outcomes in an intensive care unit of a rural hospital: A cross-sectional study. Indian J Crit Care Med 2022;26(1):39–42. DOI: 10.5005/jp-journals-10071-24075.